ASCO 2022 | Mitigating resistance in KRAS-driven cancers

Bob T. Li, MD, MPH, Memorial Sloan Kettering Cancer Center, New York, NY, elaborates on areas of unmet need for KRAS-driven non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), including intrinsic resistance, as well as mechanisms of progression. Dr Li highlights the subsequent acquisition of mutations mediating resistance to KRASG12C inhibition, such as RTK, EGFR, MET, and ROS1, which may be druggable with targeted therapies and may inform combinatorial approaches. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.